ProCE Banner Activity


Adult ADHD: What’s New?

In this interactive recording of a live CCO webinar, Maggie Sibley, PhD; Vladimir Maletic, MD, MS; and Greg Mattingly, MD, discuss diagnostic challenges and comorbidities in adult patients with ADHD as well as current and emerging treatments for adult patients with ADHD.

Pharmacists: 1.50 contact hours (0.15 CEUs)

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Nurses: 1.50 Nursing contact hours

Released: February 17, 2022

Expiration: February 16, 2023

No longer available for credit.



Vladimir Maletic

Vladimir Maletic, MD

Clinical Professor
Department of Psychiatry
USC School of Medicine
Greenville, South Carolina

Greg W. Mattingly

Greg W. Mattingly, MD

Associate Clinical Professor
Department of Psychiatry
Washington University School of Medicine
St. Charles Psychiatry Associates
St. Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by an educational grant provided by

Supernus Pharmaceuticals Inc

Target Audience

This activity is intended for physicians, nurse practitioners, registered nurses, and pharmacists engaged in the care of adult patients with ADHD.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify the unmet needs in treating ADHD in adults
  • Describe comorbidities and general treatment principles in ADHD
  • Recognize the efficacy, mechanism of action, and potential adverse events associated with new treatments for adults with ADHD
  • Assess strategies, either currently approved or in development, to improve executive function


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Vladimir Maletic, MD

Clinical Professor
Department of Psychiatry
USC School of Medicine
Greenville, South Carolina

Vladimir Maletic, MD, has disclosed that he has received consulting fees from AbbVie, Acadia, Alfasigma, Alkermes, Allergan, Eisai-Purdue, Intra-Cellular, Janssen, Lundbeck, Jazz, Otsuka, Sage, Sunovion, Supernus, and Takeda and received fees for non-CME/CE services from AbbVie, Acadia, Alkermes, Allergan, Eisai, Ironshore, Intra-Cellular, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, and Takeda.

Greg W. Mattingly, MD

Associate Clinical Professor
Department of Psychiatry
Washington University School of Medicine
St. Charles Psychiatry Associates
St. Louis, Missouri

Greg Mattingly, MD, has disclosed that he has received consulting fees from AbbVie, Acadia, Alkermes, Axsome, Eisai, Ironshore, Intracellular, Janssen, Lundbeck, Neos, Neurocrine, Otsuka, Redax, Roche, Rhodes, Sage, Sunovion, Supernus, Takeda, Teva, and Trispharma; funds for research support from AbbVie, Acadia, Alkermes, Avanir, Axsome, Boehringer Ingelheim, Emalex, Janssen, Medgenics, NLS-1 Pharma AG, Redax, Roche, Sage, Sunovion, Supernus, Takeda, and Teva; and fees for non-CME/CE services from AbbVie, Alkermes, Eisai, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, and Trispharma.

Staff Disclosure


Lisa Phipps, PharmD, PhD

Director, Science and Strategy, Neuroscience

Lisa Phipps, PharmD, PhD, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, NP, has no relevant conflicts of interest to report.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Credit Designation

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-054-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 17, 2022, through February 16, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


The goal of this activity is to improve participants’ competence in addressing the most important and most current challenges in ADHD management by providing a tightly focused update on recent advances and key clinical issues encountered in practice.